Genetic Testing Consideration: Family Impact

ICARE Newsletter Fall 2023

Community Spotlight

My paternal grandparents were my heroes. Wise beyond their time, they relished teaching our familythat knowledge is power, health is everything, and love is unconditional. Back then, Prevention healthmagazine and vitamin supplements filled their mailbox and 1960โ€™s exercise guru Jack LaLane, and health foodadvocate Euell Gibbons, beckoned new followers from a talking picture box in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-community-spotlight/

ICARE Newsletter Fall 2023

Germline EGFR Mutations and Familial Lung Cancer

A study, in which our Vanderbilt colleagues Georgia Wiesner, MD, MS (geneticist) and Kelly Taylor, MS, LCGC (genetic counselor) participated, was recently published about the inherited T790M EGFR mutation. Mutations in this gene lead to a higher risk or lung cancer and were found to be more common in the Southeast United States where there …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-germline-egfr-mutations-and-familial-lung-cancer/

ICARE Newsletter Fall 2023

Newly released ACMG Clinical Practice Resource on CHEK2 Developed Through a Group of Worldwide Experts!

A person with a pathogenic variant in the CHEK2 gene may be at an increased risk for developing breast and other cancers. This ACMG Clinical Practice Resource, published in ACMGโ€™s flagship journal, Genetics in Medicine, provides valuable information for healthcare providers caring for individuals with pathogenic variants in the CHEK2gene. This new ACMG Practice Resource …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-newly-released-acmg-clinical-practice-resource-on-chek2-developed-through-a-group-of-worldwide-experts/

Other Cancer Genetics Webinar April 2023

Communicating about Inherited Cancer Risk, Uncertainty, and Decision Making

Below you may watch an exciting presentation about communicating about inherited cancer risk, uncertainty, and decision making by Marleah Dean Kruzel, PhD from the University of South Florida.

Permanent link to this article: https://inheritedcancer.net/video40423/

ICARE Social Media Post September 2021

USA Today Article: Fighting Cancer with Your Own Family History

Check out the full ๐˜œ๐˜š๐˜ˆ ๐˜›๐˜ฐ๐˜ฅ๐˜ข๐˜บ article, featuring commentary from Dr. Tuya Pal (ICARE Founder), highlighting the importance of PALB2 as an inherited breast cancer gene: https://www.futureofpersonalhealth.com/breast-health/fighting-cancer-with-your-own-family-history/# Additional guidance is available through an impactful PALB2 practice resource recently published through ACMG: https://www.acmg.net/PDFLibrary/41436_2021_1151_OnlinePDF.pdf Reference: Tischkowitz, et al. Genet Med. 2021 Aug;23(8):1416-1423. PMID: 33976419

Permanent link to this article: https://inheritedcancer.net/post92221/

ICARE Social Media Post April 2021

Family Communication of Genetic Test Results Among Women with Inherited Breast Cancer Genes

Check out a recent article led by the ICARE team, published in the Journal of Genetic Counseling, outlining family communication of genetic test results among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Check out the full article at: https://onlinelibrary.wiley.com/doi/full/10.1002/jgc4.1356

Permanent link to this article: https://inheritedcancer.net/post40221/

ICARE Newsletter Winter 2021

Learning You Have a Mutation in an Inherited Cancer Gene: Whatโ€™s Next?

The benefits achieved through genetic testing for inherited cancer only happen by acting upon the results. This can be through guiding cancer treatment, receiving appropriate cancer risk management strategies, and sharing results with at-risk family members so they too can benefit from this information. We recently reported on results of our study, made possible through …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nlw2021/

ICARE Social Media Post January 2021

Family Sharing Resources: GeneSHARE

With the tremendous advances in gene-based care among those at risk for inherited cancer, we are trying to develop and improve tools and strategies to make it easier for more people to benefit from genetic testing. We are excited to share with you a free online toolkit called ๐—š๐—ฒ๐—ป๐—ฒ๐—ฆ๐—›๐—”๐—ฅ๐—˜, which is aimed at helping patients …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post10821/

ICARE Publication January 2021

Sharing genetic test results with family members of BRCA, PALB2, CHEK2, and ATM carriers

Abstract Objective: This study explored motivators and challenges/barriers to sharing personal genetic test results (GTR) with family members (FM). Methods: Semi-structured, in-depth interviews were conducted with 62 women who had a pathogenic or likely pathogenic (P/LP) variant in a BRCA, PALB2, CHEK2, or ATM gene. Selective qualitative data analysis focused on eliciting motivators and challenges/barriers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub10521/

ICARE Social Media Post August 2020

Inherited Prostate Cancer Risk

Over 600,000 men age 40 and older who were part of a family with at least three consecutive generations affected with prostate cancer were studied from the Utah Population Database. Findings from this study showed that: 36,000 had prostate cancer (5.9%) 2,500 had early-onset disease (7%) 4,000 had lethal disease (11.1%) 15,000 had clinically significant …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post81420/

ICARE Publication July 2020

Update on multi-gene panel testing and communication of genetic test results

Abstract With technological advances, multi-gene panel testing has become increasingly used to identify patients at risk for hereditary breast cancer (HBC). There are currently evidence-based interventions and breast cancer screening strategies that exist for cancer prevention and early detection among patients with HBC. Moreover, in addition to the personal impact of identifying HBC, this information …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub70820/

ICARE Social Media Post April 2020

PALB2: Cancer Risks and Risk Management

Gene: PALB2 Cancer Risks and Management (per NCCN version 1.2020): Women: Breast cancer risk: Elevated at 53% – Recommend annual breast MRI with contrast starting at age 30, and annual mammogram with consideration of tomosynthesis starting at age 30; Consider risk-reducing mastectomy. Ovarian cancer risk: Elevated at 5% – Manage based on family history. Men …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42820/

ICARE Social Media Post April 2020

BRCA2: Cancer Risks and Risk Management

Gene: BRCA2 Cancer Risks and Management (per NCCN version 3.2019): Women: Breast cancer risk: Elevated at 60%-70% – Recommend clinical breast exam every 6-12 months starting at age 25, annual breast MRI with contrast starting at age 25, and annual mammogram with consideration of tomosynthesis starting at age 30; consider risk-reducing mastectomy. Ovarian cancer risk: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42120/

ICARE Social Media Post April 2020

BRCA1: Cancer Risks and Risk Management

Gene: BRCA1 Cancer Risks and Management (per NCCN version 3.2019): Women: Breast cancer risk: Elevated at 60%-70% – Recommend clinical breast exam every 6-12 months starting at age 25, annual breast MRI with contrast starting at age 25, and annual mammogram with consideration of tomosynthesis starting at age 30; consider risk-reducing mastectomy. Ovarian cancer risk: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post41420/

ICARE Social Media Post April 2020

EPCAM: Cancer Risks and Risk Management

Gene: EPCAM Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 21%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 10%-38% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Men and Women: Colorectal cancer risk: Elevated at 43%-52% – Recommend colonoscopy every 1-2 years starting at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post4120/

ICARE Social Media Post March 2020

PMS2: Cancer Risks and Risk Management

Gene: PMS2 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 0%-15% – Consider risk-reducing hysterectomy. Men and Women: Colorectal cancer risk: Elevated at 12%-20% – Recommend colonoscopy every 1-2 years starting at age 20-25 Gastric cancer risk: Not well established – Consider upper endoscopy every 3-5 years beginning at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32420/

ICARE Social Media Post March 2020

Study Based on ICARE Participants with ATM and CHEK2 Mutations

Women with ATM and CHEK2 mutations have a lifetime breast cancer risk greater than 20%, which is the threshold at which screening through a breast MRI is recommended. A recently published study based on ICARE participants with ATM and CHEK2 mutations suggested that most female family members of ATM and CHEK2 mutation carriers do not …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32020/

ICARE Social Media Post March 2020

MSH6: Cancer Risks and Risk Management

Gene: MSH6 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: 17%-46% – Consider risk-reducing hysterectomy. Ovarian cancer risk: 1%-11% – Evidence is insufficient to make specific recommendations. Men and Women: Colorectal cancer risk: 15%-44% – Recommend colonoscopy every 1-2 years starting at age 20-25. Gastric cancer risk: 0%-5% – Consider upper …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31720/

ICARE Social Media Post March 2020

MSH2: Cancer Risks and Risk Management

Gene: MSH2 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 21%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 10%-38% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Men and Women: Colorectal cancer risk: Elevated at 43%-52% – Recommend colonoscopy every 1-2 years starting at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31020/

ICARE Social Media Post March 2020

MLH1: Cancer Risks and Risk Management

Gene: MLH1 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 43%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 5%-20% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Breast cancer risk: Elevated at 12%-17% – Manage same as general population. Men and Women: Colorectal cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post3320/

ICARE Newsletter Winter 2020

New Study Based on ICARE Participants with ATM & CHEK2 Mutations

We are excited to tell you about our recently published results based solely on data from ICARE participants with ATM and CHEK2 mutations. Our findings suggest most female family members of ATM and CHEK2 mutation carriers do not qualify for breast MRI screening based on family cancer history alone. This emphasizes the need to share …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-winter-2020new-study-based-on-icare-participants-with-atm-chek2-mutations/

ICARE Social Media Post October 2019

Male Breast Cancer Risk

Did you know? Beyonceโ€™s father, Matthew Knowles, was diagnosed with breast cancer. He states, โ€œwe used to think this was only an issue for women, but this is male or female.โ€ According to CBS news, โ€œhe is hoping that sharing his story as man with breast cancer will shine a light on the risk men …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post10619/